Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Nov;85(10):1452–1455. doi: 10.1054/bjoc.2001.2108

Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC)

E Baldini 1, A Ardizzoni 2, T Prochilo 1, M A Cafferata 2, L Boni 4, C Tibaldi 1, C Neumaier 3, P F Conte 1, R Rosso 2; The Italian Lung Cancer Task Force (FONICAP)2
PMCID: PMC2363940  PMID: 11720427

Abstract

To evaluate activity and toxicity of a non platinum-based triplet including Gemcitabine, Ifosfamide and Navelbine (GIN) in advanced NSCLC. Stage IIIB/IV NSCLC patients with WHO PS < 2 and bidimensionally measurable disease entered the study. Gemcitabine 1000 mg/sqm day 1 and 1000–800 mg/sqm day 4, Ifosfamide 3 g/sqm day 1 (with Mesna), Navelbine 25 mg/sqm day 1 and 25–20 mg/sqm day 4 were administered intravenously every 3 weeks. Objective responses (ORs) were evaluated every 2 courses: a maximum of 6 courses were administered in responding patients. According to Simon's optimal two-stage design more than 18 ORs out of 54 patients were required to establish the activity of this regimen. Fifty patients entered the study. Main characteristics of the 48 evaluated patients were: median age 63 years, ECOG performance status 0 = 65%, stage IV disease 79% and non-squamous histology 71%. The total number of courses administered was 200, median per patient 4 (range 1–6). Toxicities were evaluated according to WHO criteria: neutropenia grade 3–4 occurred in 47% of the courses; thrombocytopenia grade 3–4 in 6.6%; anaemia grade 3 in 3.5%. Twelve episodes of febrile neutropenia were reported and three patients required hospital admission. No toxic death was reported. Non-haematological toxicity, including skin rash, alopecia and fatigue, were generally. Twenty-five ORs (1 complete response and 24 partial responses) were obtained for a response rate of 52% (95% CI: 37.4–66.5%). One-year survival was 46.5%. This non-platinum-based outpatient triplet showed promising activity against NSCLC with myelosuppression, in particular neutropenia, being dose-limiting. The GIN regimen may represent a valuable alternative to standard platinum-based doublets and triplets in the treatment of advanced NSCLC and further studies with this platinum-free combination are warranted. © 2001 Cancer Research Campaign  http://www.bjcancer.com

Keywords: metastatic non-small-cell lung cancer, non-platinum-based regimen

Full Text

The Full Text of this article is available as a PDF (49.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldini E., Silvano G., Tibaldi C., Campoccia S., Cionini L., Conte P. Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study. Semin Oncol. 2000 Feb;27(1 Suppl 1):28–32. [PubMed] [Google Scholar]
  2. Baldini E., Tibaldi C., Chella A., Angeletti C. A., Silvano G., Andrei A., Algeri R., Conte P. F. Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 1996 Sep;7(7):747–749. doi: 10.1093/oxfordjournals.annonc.a010726. [DOI] [PubMed] [Google Scholar]
  3. Bonomi P., Kim K., Fairclough D., Cella D., Kugler J., Rowinsky E., Jiroutek M., Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623–631. doi: 10.1200/JCO.2000.18.3.623. [DOI] [PubMed] [Google Scholar]
  4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995 Oct 7;311(7010):899–909. [PMC free article] [PubMed] [Google Scholar]
  5. Comella P., Frasci G., Panza N., Manzione L., De Cataldis G., Cioffi R., Maiorino L., Micillo E., Lorusso V., Di Rienzo G. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol. 2000 Apr;18(7):1451–1457. doi: 10.1200/JCO.2000.18.7.1451. [DOI] [PubMed] [Google Scholar]
  6. Comella P., Frasci G., Panza N., Manzione L., De Cataldis G., Cioffi R., Maiorino L., Micillo E., Lorusso V., Di Rienzo G. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol. 2000 Apr;18(7):1451–1457. doi: 10.1200/JCO.2000.18.7.1451. [DOI] [PubMed] [Google Scholar]
  7. Comella P., Frasci G., Panza N., Manzione L., Lorusso V., Di Rienzo G., Cioffi R., De Cataldis G., Maiorino L., Bilancia D. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group. J Clin Oncol. 1999 May;17(5):1526–1534. doi: 10.1200/JCO.1999.17.5.1526. [DOI] [PubMed] [Google Scholar]
  8. Crawford J. Update: vinorelbine (navelbine) in non-small cell lung cancer. Semin Oncol. 1996 Apr;23(2 Suppl 5):2–7. [PubMed] [Google Scholar]
  9. Crinò L., Clerici M., Figoli F., Carlini P., Ceci G., Cortesi E., Carpi A., Santini A., Di Costanzo F., Boni C. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol. 1995 Apr;6(4):347–353. doi: 10.1093/oxfordjournals.annonc.a059183. [DOI] [PubMed] [Google Scholar]
  10. Crinò L., Scagliotti G. V., Ricci S., De Marinis F., Rinaldi M., Gridelli C., Ceribelli A., Bianco R., Marangolo M., Di Costanzo F. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999 Nov;17(11):3522–3530. doi: 10.1200/JCO.1999.17.11.3522. [DOI] [PubMed] [Google Scholar]
  11. Crinò L., Scagliotti G., Marangolo M., Figoli F., Clerici M., De Marinis F., Salvati F., Cruciani G., Dogliotti L., Pucci F. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1997 Jan;15(1):297–303. doi: 10.1200/JCO.1997.15.1.297. [DOI] [PubMed] [Google Scholar]
  12. Eberhardt W., Niederle N. Ifosfamide in non-small cell lung cancer: a review. Semin Oncol. 1992 Feb;19(1 Suppl 1):40–48. [PubMed] [Google Scholar]
  13. Giaccone G., Splinter T. A., Debruyne C., Kho G. S., Lianes P., van Zandwijk N., Pennucci M. C., Scagliotti G., van Meerbeeck J., van Hoesel Q. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1998 Jun;16(6):2133–2141. doi: 10.1200/JCO.1998.16.6.2133. [DOI] [PubMed] [Google Scholar]
  14. Gridelli C., Frontini L., Perrone F., Gallo C., Gulisano M., Cigolari S., Castiglione F., Robbiati S. F., Gasparini G., Ianniello G. P. Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators. Br J Cancer. 2000 Sep;83(6):707–714. doi: 10.1054/bjoc.2000.1341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Loprevite M., Favoni R. E., de Cupis A., Pirani P., Merlo F., Grossi F., Ardizzoni A. Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity. Int J Oncol. 1999 Oct;15(4):787–792. doi: 10.3892/ijo.15.4.787. [DOI] [PubMed] [Google Scholar]
  16. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  17. Morere J. F., Piperno-neumann S., Brunet A., Boaziz C., Kohn M., Bouillet T., Breau J. L. Vinorelbine and ifosfamide for unresectable non-small cell lung cancer. Lung Cancer. 1997 Aug;18(1):95–100. doi: 10.1016/s0169-5002(97)00044-5. [DOI] [PubMed] [Google Scholar]
  18. Pirker R., Krajnik G., Zöchbauer S., Malayeri R., Kneussl M., Huber H. Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 1995 Oct;6(8):833–835. doi: 10.1093/oxfordjournals.annonc.a059324. [DOI] [PubMed] [Google Scholar]
  19. Sculier J. P., Klastersky J., Giner V., Bureau G., Thiriaux J., Dabouis G., Efremidis A., Ries F., Berchier M. C., Sergysels R. Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol. 1994 Feb;12(2):353–359. doi: 10.1200/JCO.1994.12.2.353. [DOI] [PubMed] [Google Scholar]
  20. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1–10. doi: 10.1016/0197-2456(89)90015-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES